Literature DB >> 16823720

Effects of chronic alcoholic disease on magnocellular and parvocellular hypothalamic neurons in men.

E V Sivukhina1, A A Dolzhikov, Iu E Morozov, G F Jirikowski, V Grinevich.   

Abstract

Although numerous data showing severe morphological impairment of magnocellular and parvocellular hypothalamic neurons due to chronic alcoholic consumption have been gathered from animal experiments, only one study (Harding et al., 1996) was performed on POST MORTEM human brain. This study showed a reduction in the number of vasopressin (VP)-immunoreactive neurons in the supraoptic (SON) and paraventricular (PVN) nuclei, but did not provide any data regarding the effect of chronic alcohol intake on human parvocellular neurons. In order to assess whether the changes observed in the animal model also occur in humans and provide a structural basis for the results of clinical tests, we performed immunohistochemical and morphometric analysis of magnocellular (VP and oxytocin, OT) and parvocellular (corticotropin-releasing hormone, CRH) neurons in post-mortem brains of patients afflicted with chronic alcoholic disease. We analyzed 26-male alcoholics and 22 age-matched controls divided into two age groups--"young" (< 40 yr) and "old" (> 40 yr). Hypothalamic sections were stained for OT, VP, and CRH. The analysis revealed: 1) decrease in VP-immunoreactivity in the SON and PVN as well as OT-immunoreactivity in the SON in alcoholic patients; 2) increase in OT-immunoreactivity in the PVN; 3) increase in CRH-immunoreactivity in parvocellular neurons in the PVN. Furthermore, the proportion of cells containing CRH and VP was increased in alcoholics. These findings indicate that chronic alcohol consumption does indeed impair the morphology of magnocellular neurons. The enhancement of CRH-immunoreactivity and increased co-production of CRH and VP in parvocellular neurons may be due to a decline in glucocorticoid production, implied by the hypoplasic impairment of adrenal cortex we observed in alcoholics during the course of this study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823720     DOI: 10.1055/s-2006-944522

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  14 in total

1.  Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol.

Authors:  Kaeli W Yuen; Joseph P Garner; Dean S Carson; Jennifer Keller; Anna Lembke; Shellie A Hyde; Heather A Kenna; Lakshika Tennakoon; Alan F Schatzberg; Karen J Parker
Journal:  J Psychiatr Res       Date:  2013-12-28       Impact factor: 4.791

Review 2.  Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date.

Authors:  Mary R Lee; Matthew C H Rohn; Gianluigi Tanda; Lorenzo Leggio
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

Review 3.  Oxytocin for the treatment of drug and alcohol use disorders.

Authors:  Mary R Lee; Elise M Weerts
Journal:  Behav Pharmacol       Date:  2016-12       Impact factor: 2.293

4.  Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination.

Authors:  Petra S van Nieuwenhuijzen; Leonora E Long; Glenn E Hunt; Jonathon C Arnold; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2010-08-21       Impact factor: 4.530

5.  Oxytocin Reduces Alcohol Cue-Reactivity in Alcohol-Dependent Rats and Humans.

Authors:  Anita C Hansson; Anne Koopmann; Stefanie Uhrig; Sina Bühler; Esi Domi; Eva Kiessling; Roberto Ciccocioppo; Robert C Froemke; Valery Grinevich; Falk Kiefer; Wolfgang H Sommer; Sabine Vollstädt-Klein; Rainer Spanagel
Journal:  Neuropsychopharmacology       Date:  2017-11-01       Impact factor: 7.853

6.  Conditioned social preference and reward value of activating oxytocin-receptor-expressing ventral tegmental area neurons following repeated daily binge ethanol intake.

Authors:  Joanna Peris; Katye Totten; Darrice Montgomery; Hannah Lester; Arnika Weatherington; Brian Piotrowski; Sam Sowell; Kristen Doyle; Karen Scott; Yalun Tan; Kaley A MacFadyen; Hannah Engle; Annette D de Kloet; Eric G Krause
Journal:  Alcohol Clin Exp Res       Date:  2022-01-07       Impact factor: 3.455

Review 7.  Early adverse experience and substance addiction: dopamine, oxytocin, and glucocorticoid pathways.

Authors:  Sohye Kim; Stephanie Kwok; Linda C Mayes; Marc N Potenza; Helena J V Rutherford; Lane Strathearn
Journal:  Ann N Y Acad Sci       Date:  2016-08-10       Impact factor: 5.691

Review 8.  From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?

Authors:  I S McGregor; P D Callaghan; G E Hunt
Journal:  Br J Pharmacol       Date:  2008-05       Impact factor: 8.739

Review 9.  Oxytocin treatment for alcoholism: Potential neurocircuitry targets.

Authors:  Joanna Peris; Madeline R Steck; Eric G Krause
Journal:  Neuropharmacology       Date:  2020-04-15       Impact factor: 5.250

10.  Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Megan Moran-Santa Maria; Kathleen T Brady
Journal:  Psychopharmacology (Berl)       Date:  2013-04-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.